Skip to main content

LCD L38303: MolDX: Prostate Cancer Genomic Classifier Assay for Men with Localized Disease

LCD L38303, MolDX: Prostate Cancer Genomic Classifier Assay for Men with Localized Disease, is the Local Coverage Determination that CGS Administrators, LLC applies to claims from 2 states (KY, OH), effective 2026-03-19 and first in force 2020-11-09. The policy text runs 403 words, and its billing and coding article A58371 lists 1 ICD-10-CM codes that support medical necessity for 3 procedure codes. 3 other contractor versions share this title, so the criteria depend on where the service is furnished. Counting every linked billing and coding article, this one lists 1 covered ICD-10-CM code: the same total as L38292 (Palmetto GBA, 1 code, revised 2025-07-03) and the same total as L38339 (Noridian Healthcare Solutions, LLC, 1 code, revised 2026-02-05).

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database LCD export: MCD release November 12, 2026 (effective November 8, 2026); Medicare Coverage Database billing and coding articles: MCD release November 12, 2026 (effective November 8, 2026). Next CMS release: weekly, every Thursday.

Contractor
CGS Administrators, LLC
States and territories
2
KY OH
Revision effective
2026-03-19
Original effective
2020-11-09
Policy text
403 words
Covered ICD-10 codes (articles)
1

Where this LCD applies

Each contract number is a jurisdiction on the remittance; the policy binds claims processed under these contracts and no others.

Contracts that apply LCD L38303
ContractContractorTypeStates
15102CGS Administrators, LLCMAC - Part BKY
15202CGS Administrators, LLCMAC - Part BOH
15101CGS Administrators, LLCMAC - Part AKY
15201CGS Administrators, LLCMAC - Part AOH

Billing and coding article A58371: diagnoses and procedure codes

Since 2019 the codes live in the companion article rather than the LCD. Billing and Coding A58371 (Billing and Coding: MolDX: Prostate Cancer Genomic Classifier Assay for Men with Localized Disease) carries the diagnosis and procedure lists the contractor loads as the claims edit. CPT codes are shown as bare numbers because the descriptors are licensed by the AMA; HCPCS Level II descriptors are public and shown. Each article below opens its complete covered and non-covered ICD-10-CM lists, by group and with the contractor's group instructions, and the LCD code lookup answers whether one diagnosis is covered for one procedure code in a given state.

Coverage is only half of the claim edit: when two of the listed procedure codes are billed on the same date, test the pair against the NCCI edits before relying on both being paid.

A58371: Billing and Coding: MolDX: Prostate Cancer Genomic Classifier Assay for Men with Localized Disease (Billing and Coding, effective 2023-12-21)

Covered ICD-10-CM codes
1
1 group
Non-covered ICD-10-CM codes
0
Procedure codes listed
3
Full article
cms.gov record
First 1 covered ICD-10-CM codes in A58371
ICD-10-CMDescription (FY2027)
C61Malignant neoplasm of prostate

Procedure codes: 0047U, 81541, 81542.

Coverage indications, limitations and medical necessity

This is a limited coverage policy for Genomic derived tests that assess risk in localized (non-metastatic) prostate cancer. The review is focused on the Decipher® Prostate Cancer Classifier Assay (identified as Decipher® to follow). The test is considered reasonable and necessary to help identify men with localized Prostate Cancer and a life expectancy of at least 10 years who are good candidates for active surveillance according to the most recent National Comprehensive Cancer Network (NCCN) guidelines.

Decipher® is covered for men with prostate cancer:

With localized or biochemically recurrent adenocarcinoma of the prostate (i.e. no clinical evidence of metastasis) who have a life expectancy of greater than or equal to 10 years if they are a candidate for and are considering (or being considered for) at least one of the following:

• Conservative management and yet would be eligible for definitive therapy (radical prostatectomy (RP), radiation or brachytherapy), or;

• Radiation therapy and yet would be eligible for the addition of a brachytherapy boost, or;

• Radiation therapy and yet would be eligible for the addition of short-term androgen deprivation therapy(ADT), or;

• Radiation therapy with short-term ADT yet would be eligible for the use of long term ADT, or;

• Radiation with standard ADT yet would be eligible for systemic therapy intensification using next generation androgen signaling inhibitors or chemotherapy, or;

• Observation post-prostatectomy yet would be eligible for the addition of post-operative adjuvant radiotherapy, or;

• Salvage radiotherapy post-prostatectomy yet would be eligible for the addition of ADT.

The following criteria must also be met for coverage:

• The assay is performed on formalin-fixed paraffin embedded (FFPE) prostate biopsy tissue with at least 0.5 mm of linear tumor diameter or FFPE tissue from a prostate resection specimen, and;

• Result will be used to determine treatment according to established practice guidelines, and;

• Patient has not received pelvic radiation or ADT prior to the biopsy or prostate resection specimen, and;

• Patient is monitored for disease progression according to established standard of care

Other genomic tests that demonstrate an equivalent analytical validity and clinical validity will be considered reasonable and necessary for the same indications. Analytical and clinical validity will be assessed as part of a thorough and comprehensive technical assessment (TA) by the Molecular Diagnostic Services Program (MolDX®) and will similarly attain coverage for indications that are supported by the evidence and intended use within the scope of this policy.

Summary of evidence (opening)

Background

In 2017, over 160,000 men in the United States (U.S.) were diagnosed with prostate cancer, which accounted for 9.6% of all new cancer diagnoses. 1 Clinically localized prostate cancer accounts for ~80% of newly diagnosed cases. 1 The NCCN, classifies these men into risk groups based on clinical and pathological features, which are intended to be used in conjunction with life expectancy estimates to select optimal treatment approaches. 2 Prostate cancer is a heterogeneous disease, which to better risk stratify this patient cohort was the creation of favorable and unfavorable intermediate risk disease groups developed by Zumsteg and Spratt at Memorial Sloan Kettering, now adopted by NCCN guidelines. 3 Recommendations for the treatment of prostate cancer are made based on the risk category of the cancer and additional considerations as noted in Table 1 below.

The primary treatment decisions in localized prostate cancer that are guided by prognosis are the use of definitive therapy versus conservative management with active surveillance, the addition of ADT to radiotherapy, the addition of brachytherapy to external beam radiotherapy, the use of long versus short-term ADT with radiotherapy, and the incorporation of newer forms of more potent ADT such as abiraterone. 2 Similarly, the primary treatment decisions after a patient has undergone a RP include the addition of adjuvant radiotherapy and addition of ADT to post-operative salvage radiotherapy. These treatment recommendations are based on multiple trials, though these guidelines provide little guidance regarding how to select the optimal therapy including how best to personalize treatment intensification or de-escalation.

Table 1: NCCN 2018 V4 - Localized Prostate Cancer Risk Stratification and Treatment

The contractor cites 1 sources in the bibliography; the full summary and analysis of evidence are in the CMS record.

Dates, lineage and related policies

Original determination effective
2020-11-09
Current revision effective
2026-03-19
Last reviewed by the contractor
2026-03-10
MCD version
13

Other related documents: A58368 (Response to Comments).

Using this policy on a claim

Match the documented indication to the covered indications above before the service is scheduled, carry a diagnosis from the article's covered list on the claim line (the diagnosis coverage checker tests one code pair against every article that applies in a state), and keep the elements the documentation section asks for in the record, because the contractor can request it later through medical review. A denial under this policy arrives as CARC 50 with remark N115; the LCD lookup guide walks through the appeal path and the Advance Beneficiary Notice rules, and the CGS Administrators, LLC hub lists every other active policy from the same contractor.

The same policy title at other contractors

Contractors often adopt each other's policies and then revise them separately, so the criteria and the diagnosis lists drift apart. The topic comparison lines up every version.

For teams evaluating QuickIntell software

Where QuickIntell fits with this policy

If your team repeatedly reviews local coverage policies, explore QuickAuth for requirement checks, documentation and status tracking with staff oversight. Confirm the applicable policy, supported workflow and review responsibilities. Use QuickRCM to evaluate the separate claim and denial workflow.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions

What does LCD L38303 cover?

This is a limited coverage policy for Genomic derived tests that assess risk in localized (non-metastatic) prostate cancer. The review is focused on the Decipher® Prostate Cancer Classifier Assay (identified as Decipher® to follow). The test is considered reasonable and necessary to help identify men with localized Prostate Cancer and a life expectancy of at least 10 years who are good candidates for active… The full 403-word policy text is reproduced below from the Medicare Coverage Database export of November 12, 2026.

Which states does LCD L38303 apply to?

CGS Administrators, LLC applies it to Medicare claims in 2 states: KY, OH. It binds only that contractor; 3 other contractor versions of this title govern other jurisdictions, and elsewhere the same service is judged under the local contractor's own policy or, where none exists, claim by claim.

Which diagnosis codes support medical necessity under LCD L38303?

The companion billing and coding article A58371 lists 1 ICD-10-CM codes in 1 group that support medical necessity; the first 1 appear on this page, where the complete list opens by group with the contractor's group instructions.

How do I appeal a denial under LCD L38303?

A denial under LCD L38303 carries claim adjustment reason code 50 with remark code N115. Compare the documented indication with the policy's covered indications and article A58371's 1 covered diagnosis codes, then file a redetermination with CGS Administrators, LLC within 120 days, record attached. If the service falls outside the policy, bill the patient only with a valid Advance Beneficiary Notice signed before the service.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

The policy text and code lists are reproduced from the CMS Medicare Coverage Database export as an operational reference. Verify against the current LCD and article on cms.gov before billing; coverage depends on the full record and the contractor. Not legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.